The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 43 | — | 20.1x | Near average | |
Growth | 52 | — | 5.6% | Near average | |
Quality | 17 | -47.3% | 7.6% | Below average | |
Safety | 38 | 1.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Grace Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Grace Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
GRCE stock shows complete stability in the target price at 4 dollars over the past 7 and 30-day periods, with a total absence of analyst Dispersion due to only one analyst currently covering the stock. This consistency reflects an optimistic outlook in terms of price compared to the current price (2.2 dollars), but it lacks collective confirmation from other research institutions.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.